Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2004 2
2005 3
2008 2
2010 1
2011 1
2012 1
2013 2
2014 2
2015 2
2016 1
2017 2
2018 8
2019 2
2020 2
2021 5
2022 4
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas EM, Armstrong A, Im SA, Song CG, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugère C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer CE, Tutt ANJ. Ganz PA, et al. Among authors: tutt anj. J Clin Oncol. 2024 Apr 10;42(11):1288-1300. doi: 10.1200/JCO.23.01214. Epub 2024 Feb 1. J Clin Oncol. 2024. PMID: 38301187 Clinical Trial.
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
Harvey-Jones E, Raghunandan M, Robbez-Masson L, Magraner-Pardo L, Alaguthurai T, Yablonovitch A, Yen J, Xiao H, Brough R, Frankum J, Song F, Yeung J, Savy T, Gulati A, Alexander J, Kemp H, Starling C, Konde A, Marlow R, Cheang M, Proszek P, Hubank M, Cai M, Trendell J, Lu R, Liccardo R, Ravindran N, Llop-Guevara A, Rodriguez O, Balmana J, Lukashchuk N, Dorschner M, Drusbosky L, Roxanis I, Serra V, Haider S, Pettitt SJ, Lord CJ, Tutt ANJ. Harvey-Jones E, et al. Among authors: tutt anj. Ann Oncol. 2024 Apr;35(4):364-380. doi: 10.1016/j.annonc.2024.01.003. Epub 2024 Jan 19. Ann Oncol. 2024. PMID: 38244928 Free article.
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
Baxter JS, Brough R, Krastev DB, Song F, Sridhar S, Gulati A, Alexander J, Roumeliotis TI, Kozik Z, Choudhary JS, Haider S, Pettitt SJ, Tutt ANJ, Lord CJ. Baxter JS, et al. Among authors: tutt anj. Mol Oncol. 2024 Feb;18(2):369-385. doi: 10.1002/1878-0261.13537. Epub 2023 Oct 22. Mol Oncol. 2024. PMID: 37866880 Free PMC article.
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Pettitt SJ, Shao N, Zatreanu D, Frankum J, Bajrami I, Brough R, Krastev DB, Roumeliotis TI, Choudhary JS, Lorenz S, Rust A, de Bono JS, Yap TA, Tutt ANJ, Lord CJ. Pettitt SJ, et al. Among authors: tutt anj. Oncogene. 2023 Sep;42(36):2701-2709. doi: 10.1038/s41388-023-02782-8. Epub 2023 Jul 25. Oncogene. 2023. PMID: 37491606 Free PMC article.
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Zelceski A, Francica P, Lingg L, Mutlu M, Stok C, Liptay M, Alexander J, Baxter JS, Brough R, Gulati A, Haider S, Raghunandan M, Song F, Sridhar S, Forment JV, O'Connor MJ, Davies BR, van Vugt MATM, Krastev DB, Pettitt SJ, Tutt ANJ, Rottenberg S, Lord CJ. Zelceski A, et al. Among authors: tutt anj. Cell Rep. 2023 May 30;42(5):112484. doi: 10.1016/j.celrep.2023.112484. Epub 2023 May 9. Cell Rep. 2023. PMID: 37163373 Free article.
Systemic Therapy for Hereditary Breast Cancers.
Harvey-Jones EJ, Lord CJ, Tutt ANJ. Harvey-Jones EJ, et al. Among authors: tutt anj. Hematol Oncol Clin North Am. 2023 Feb;37(1):203-224. doi: 10.1016/j.hoc.2022.08.018. Hematol Oncol Clin North Am. 2023. PMID: 36435611 Free article. Review.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Among authors: tutt anj. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
Opinion: PARP inhibitors in cancer-what do we still need to know?
Wicks AJ, Krastev DB, Pettitt SJ, Tutt ANJ, Lord CJ. Wicks AJ, et al. Among authors: tutt anj. Open Biol. 2022 Jul;12(7):220118. doi: 10.1098/rsob.220118. Epub 2022 Jul 27. Open Biol. 2022. PMID: 35892198 Free PMC article. Review.
TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer.
Beatson RE, Parente-Pereira AC, Halim L, Cozzetto D, Hull C, Whilding LM, Martinez O, Taylor CA, Obajdin J, Luu Hoang KN, Draper B, Iqbal A, Hardiman T, Zabinski T, Man F, de Rosales RTM, Xie J, Aswad F, Achkova D, Joseph CR, Ciprut S, Adami A, Roider HG, Hess-Stumpp H, Győrffy B, Quist J, Grigoriadis A, Sommer A, Tutt ANJ, Davies DM, Maher J. Beatson RE, et al. Among authors: tutt anj. Cell Rep Med. 2021 Dec 21;2(12):100473. doi: 10.1016/j.xcrm.2021.100473. eCollection 2021 Dec 21. Cell Rep Med. 2021. PMID: 35028614 Free PMC article.
46 results